From: Low expression levels of hepsin and TMPRSS3 are associated with poor breast cancer survival
 | TMPRSS1 expressiona | TMPRSS3 expressiona | ||||
---|---|---|---|---|---|---|
Clinical variable | n (%) | P | Median / IQR | n (%) | P | Median / IQR |
Tumor type | Â | 0.002 | Â | Â | NS | Â |
 Benign | 16 (11.3) |  | 0.27 / 0.57 | 23 (12.1) |  | 0.98 / 0.56 |
 Malignant | 125 (88.7) |  | 0.96 / 2.10 | 167 (87.9) |  | 0.92 / 1.74 |
Tumor grade | Â | 0.000015 | Â | Â | 0.0002 | Â |
 I | 24 (19.5) | 0.000007b | 2.03 / 2.74 | 28 (17.3) | 0.016b | 1.76 / 2.80 |
 II | 51 (41.5) | NSc | 1.67 / 2.41 | 74 (45.7) | NSc | 1.29 / 2.03 |
 III | 48 (39.0) | 0.000004d | 0.55 / 0.88 | 60 (37.0) | 0.0001d | 0.55 / 0.84 |
ER status | Â | 0.000003 | Â | Â | 0.0027 | Â |
 Negative | 40 (32.5) |  | 0.45 / 0.84 | 50 (31.1) |  | 0.55 / 0.84 |
 Positive | 83 (67.5) |  | 1.67 / 2.44 | 111 (68.9) |  | 1.24 / 2.34 |
PR status | Â | 0.001 | Â | Â | 0.0076 | Â |
 Negative | 56 (45.5) |  | 0.59 / 1.39 | 70 (43.5) |  | 0.67 / 1.21 |
 Positive | 67 (54.5) |  | 1.53 / 2.57 | 91 (56.5) |  | 1.32 / 2.41 |
HER2 status | Â | 0.001 | Â | Â | 0.017 | Â |
 Negative | 99 (83.9) |  | 1.12 / 2.25 | 130 (84.4) |  | 1.08 / 2.46 |
 Positive | 19 (16.1) |  | 0.35 / 0.75 | 24 (15.6) |  | 0.58 / 0.89 |
ER/PR/HER2 status | Â | 0.001 | Â | Â | NS | Â |
 Triple-negative | 24 (20.3) |  | 0.49 / 0.98 | 29 (19.2) |  | 0.69 / 1.86 |
 Non-triple-negative | 94 (79.7) |  | 1.12 / 2.33 | 122 (80.8) |  | 1.09 / 1.81 |